Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer.

Abstract

AIM:

To investigate the effectiveness and adverse effects of gemcitabine by fixed-dose rate infusion plus oxaliplatin (GEMOX regimen) as second-line therapy for advanced ovarian cancer.

METHODS:

64 patients with advanced ovarian cancer were divided into an experimental group (44 cases) and a control group (20 cases). The experimental group was treated with continuous intravenous infusion of gemcitabine at 1000 mg/m(2) with a fixed-dose rate of 10 mg/m(2)/min, on days 1 and 8 and oxaliplatin at 100 mg/m(2) on day 1, IVGTT, repeated every 3 weeks. The control group was treated with intravenous infusion of gemcitabine at 1000 mg/m(2) within 30 min on days 1 and and oxaliplatin at 100 mg/m(2) on day 1, IVGTT, again repeated every 3 weeks. CT scans or MRI were used for review every 1-2 cycles.

RESULTS:

The effective rate in the experimental group was significantly high than control group (43.2% vs 35.0%; P < 0.05), with no obvious difference of hematologic or non-hematologic toxicity between the two groups (P > 0.05).

CONCLUSION:

GEMOX regimen is very effective to treat advanced ovarian cancer, with low toxicity, good tolerance and improved life quality in patients.

• Authors: Shao-Fei Yuan, Lian-Ping Zhang, Lin-Jia Zhu, Wen-Jun Chen, Wei-E Zheng, Jian-Ping Xiong
• Journal: Asian Pacific journal of cancer prevention : APJCP (Asian Pac J Cancer Prev) Vol. 14 Issue 6 Pg. 3949-53 ( 2013) ISSN: 2476-762X [Electronic] Thailand
• PMID: 23886213 (Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Organoplatinum Compounds
• Deoxycytidine

Topics

• Adenocarcinoma, Clear Cell (drug therapy, mortality, pathology)
• Adenocarcinoma, Mucinous (drug therapy, mortality, pathology)
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Case-Control Studies
• Cystadenocarcinoma, Serous (drug therapy, mortality, pathology)
• Deoxycytidine (analogs & derivatives, therapeutic use)
• Endometrial Neoplasms (drug therapy, mortality, pathology)
• Female
• Follow-Up Studies
• Humans
• Middle Aged
• Neoplasm Staging
• Organoplatinum Compounds (therapeutic use)
• Ovarian Neoplasms (drug therapy, mortality, pathology)
• Prognosis
• Quality of Life
• Survival Rate